Omagine Inc.(OTCMKTS:OMAG) looks to be ending the year with a bang which seems fitting considering it started the year in much the same way running from just over $0.50 in February to highs near $3 per share.
After a quiet period for the last several months OMAG exploded in October after the they announced the ”Multi-Billion Dollar Agreement With Oman.” What is significant about OMAG latest run is that this time the stock has not given back any gains and looks to be headed towards 52 weak highs.
Omagine, Inc. organized Omagine LLC under the laws of Oman to design, develop, own and operate a tourism and real-estate development project in Oman named the Omagine Project. The Omagine Project is estimated to cost approximately $2.5 billion to design, develop and construct.
Omagine Inc.(OTCMKTS:OMAG) has had this project in development now for close to 10 years even before the Company changed their name to Omagine, Inc. in June 2007. As early as 2006 when the Company was still Alfa International Corp. and then later Alfa International Holdings Corp. they were in Oman working on this.
Omagine, Inc. is a publicly traded company conducting real-estate development, tourism and entertainment business activities through either its 60% owned subsidiary Omagine LLC or its 100% owned subsidiary Journey of Light, Inc. The Company is focused on real-estate, entertainment and hospitality opportunities in the Middle East and North Africa (the “MENA Region”) which is one of the fastest growing tourist destinations in the world.
Governments in the MENA Region are seeking to diversify their economies and create employment for their citizens via the development of tourism destination projects. It is the Company’s opinion that this governmental strategic vision combined with the enormous financial resources in the MENA Region will continue to present superb development opportunities. The Company presently focuses the majority of its efforts on the business of Omagine LLC and specifically on the Omagine Project.
On October 2 OMAG announced the $2.5 billion Omagine Project a planned integration of cultural, entertainment and residential components, including: hotels, commercial buildings, retail establishments and more than two thousand residences to be developed for sale. It will be developed on one million square meters (245 acres) of beachfront land (the “Omagine Site”) facing the Gulf of Oman just west of the capital city of Muscat and approximately six miles from Muscat International Airport.
For more info on OMAG Please Subscribe below, also you should know we have Something Huge Coming!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The Company owns 60% of Omagine LLC. The other Omagine LLC shareholders are: i. the office of Royal Court Affairs (“RCA”), which owns 25%, and ii. two subsidiaries of Consolidated Contractors International Company, SAL (“CCIC”), which collectively own 15%.
The Company, RCA and the two CCIC subsidiaries are parties to a legally binding Shareholder Agreement which, among other things, provides for: i. initially capitalizing Omagine LLC at 150,000 Omani Rials [$390,000], and ii. Increasing Omagine LLC’s capital to 26,988,125 Omani Rials [$70,169,125] within a 6 to 12 month period following the signing of the Development Agreement, and iii. a payment-in-kind investment of the land constituting the Omagine Site (the “PIK”).
The value of the land constituting the Omagine Site is conservatively but informally estimated by local real-estate brokers to be in excess of $700 million. The legally binding contract between all parties was signed on October 2, 2014.
The Omagine Project will include cultural, heritage, educational, entertainment and residential components, including: a high culture theme park containing seven pearl shaped buildings, each approximately 60 feet in diameter, associated exhibition buildings, a boardwalk, an open air amphitheater and stage.
Also planned are open space green areas; a canal and an enclosed harbor and marina area; associated retail shops and restaurants, entertainment venues, boat slips, and docking facilities; a five-star resort hotel, a four-star resort hotel and possibly a three or four-star hotel; commercial office buildings; shopping and retail establishments integrated with the hotels, and approximately two thousand residences to be developed for sale.
Conclusion: OMAG is an old shell that has been around for many years since the mid 90’s before it went bankrupt on a higher exchange. The Company has undergone a significant number of name changes and reverse stock splits over the years before changing their name to Omagine Inc. in 2007.
For the past 10 years the Company has been focused on bringing The Omagine Project to fruition and the recently announced Development Agreement (“DA”) brings much hope that this deal will now happen.
The Company has maintained a loyal shareholder base over the past 10 years primarily on agoracom.com where OMAG has been a crowd favorite since 2006. Since that time OMAG has been highly volatile swinging from $0.50 on the low side to runs as high as $14 per share.
Currently trading at a $50 million market valuation OMAG continues to trade strong. Some investors swear this one is going into the stratosphere others are saying the opposite, once thing is clear; OMAG time to shine is here and as it comes into the spotlight in the coming days and the Omagine Project is traded on things are going to get incredibly exciting around here.
Disclosure: we hold no position in OMAG either long or short and we have not been compensated for this article.
On the cusp of a cure for COVID, one of the most promising yet under-the-radar biotech stocks on the OTC is generating much well-deserved buzz in the scientific community and is poised to go viral.
Bioxytran Inc. (OTCMKTS: BIXT) over the weekend had their phase 2 top-line results published in the peer-reviewed journal “Vaccines.” There is a not-so-subtle tinge of irony in that name because while their drug is nothing like a vaccine, there is no doubt about its efficacy– 100% PCR negative rate by day 7 versus 6% in placebo. The medical journal article was titled “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial.” This is a landmark journal article because – until now – only one other drug, Harvoni, had equaled a 100% responders rate in the past decade. Harvoni ultimately ended up being a cure for Hepatitis C Virus.
At this point in Bioxytran’s drug development pipeline, it essentially has a functional cure for COVID-19 that simply needs a pivotal phase 3 trial to show the true extent of their discovery. Their drug is a galectin antagonist, which neutralizes the now infamous spike proteins by placing a carbohydrate sheath over the spikes making attachment to the cell impossible. The carbohydrates binding grip is so tight on the virus that it carries it around in the blood until it is eventually filtered out by the liver and excreted.
If solving the pandemic wasn’t enough, the company recently reported that in vitro studies suggest the drug would be effective in Influenza and RSV. Yet despite the fact that this one drug could seemingly end upper respiratory infections, which most of us refer to as a “common cold,” it has a nominal market cap of just $50 million.
For the past three months, BIXT has been teasing this peer-reviewed article as a catalyst and a major value inflection point for the company. Despite that, investors haven’t gotten the hint, and have been steadily selling into this inflection point. Even though the company has yet to report it in a press release, the scientific community is understandably going crazy over it. Investors, however, are seemingly oblivious to the viral traffic and simply not paying attention to the sheer magnitude of the discovery–a functional cure for COVID and the methodology to seemingly combat any virus.
One of the reasons peer review is so important for a biotech is that major media outlets won’t touch the science without it. With its publication, this article means that BIXT now has an opportunity to tell its story on network media. The biggest risk that investors now face in BIXT is FOMO, driven by an unexpected media appearance that ushers unbridled buying into the name and leaves tepid investors chasing up.
If the article itself wasn’t enough, their peer-reviewed article was picked up by a major biotech influencer on Twitter, quickly garnering more than 100k hits. The influencer, Chris Turnbull, summarized the article highlighting key points like the rapid viral clearance in 3 days through entry inhibition and suggested the ideal use is when you know you were exposed. He hammered the point that ProLectin-M was for standard-risk patients and that Paxlovid was for high-risk groups with at least one medical condition.
This discovery changes the COVID landscape permanently. Multi-billion dollar antiviral drugs like Paxlovid and Lagevrio can’t hold a candle to the viral clearing power of BIXT’s galectin antagonist. Looking at the Twitter account of BIXT Chief Commercial Officer Michael Sheikh, it’s clear that there are some ongoing discussions with big pharma that have not yielded any fruit. But big pharma may not be their only option. BIXT has also said they are looking to partner with companies with large cash balance sheets. Both galectin antagonist companies Galectin Therapeutics (NASDAQ: GALT) and Galecto Bioscience (NASDAQ: GLTO) fit the profile and are the subject of a number of relatively supportive tweets by Sheikh. Sleuthing Sheikh’s LinkedIn profile reveals hardcore evidence of that sort of dealmaking with clusters of top executives in certain companies and networking, which suggests significant activity among their larger Galectin-focused peers. In an emerging growth interview, the CCO did say that he got a lot of business cards and was networking.
There exists a huge chasm between the current market cap and what it ought to be given that it successfully completed a phase 2 and nailed the endpoint with a perfect score. The CCO described in an Emerging Growth video how valuations work and a number of comparables in the $500 million range for a number of disease indications that BIXT is developing. The stock has a very tiny float of 19 million with an OS of 123 million. This represents a float of 15% and insiders own over 60%. There is no dilution from the convertible notes as they have company-friendly terms that allow up to 5% conversion into restricted common stock. In an Emerging Growth interview a couple of months ago, the CCO acknowledged the stock’s current challenge, indicating a legacy seller was responsible for half the daily volume and was almost gone. In early March after a ZeroHedge article was published, the stock went on a record run to $1.05 in a matter of minutes before short forces brought it back down. On March 7th it looks like the seller ran out of inventory for the day and the demand just lifted the stock price allowing it to go through a short period of natural price discovery. The long-term legacy seller seems to be at the end of his block, which means any news announcement could push the stock higher.
Low-Risk Explosive Reward Profile
There is no doubt that BIXT has incredible potential yet the stock continues to languish. With the anemic volume, it’s very difficult to diagnose what the root cause is for the disconnect from the comparable valuations established by big pharma in the $500 million region and BIXT’s current $50M cap. If one article that generated a little bit of buying pushed it to the brink of explosiveness, perhaps there is more stock from this legacy seller that is still controlling the narrative.
Upcoming Catalysts
For the investor with a longer-term view, BIXT represents a safe place to park funds for explosive returns. The upcoming catalysts are a dosing of patients in India for the dose optimization trial, a potential IND from the FDA, and of course, the announcement of the peer-reviewed journal article. While it’s uncertain which catalyst will send the stock into overdrive it’s abundantly clear this is one of the most undervalued stocks in OTC.
Pound-for-Pound Comparison of Paxlovid and PLM
Paxlovid also helped lower the length of time people with underlying medical conditions were infectious. However, Paxlovid is not a very effective drug and is walking a tightrope with respect to its approval as more and more real-world data reveals their toxicity.
Here is a chart capture from the company’s latest scientific webinar that shows a side-by-side comparison for illustrative purposes. The charts show that Paxlovid can barely turn 30% of the patients PCR negative by day 20 whereas a majority of the PLM patients were PCR negative on day 3. This is an absolute game-changer in controlling the pandemic. The other thing that this peer-reviewed journal highlighted is that the symptoms were eliminated and without those symptoms, people were unlikely to develop Long COVID. It’s very reasonable to believe that PLM stops Long COVID due to its mechanism of action as well as the fact that it appeared to eliminate symptoms in this trial, as seen in the picture below. While it’s nice that Paxlovid stops hospitalization and death, PLM takes it to a new level by making you feel better faster and eliminating the risk of Long COVID.
Investment Summary
Bioxytran is not only sitting on a solution for COVID and a possible end to the pandemic, but it appears they can also treat Long COVID and a number of viruses. All this information is out there in the public domain and investors seem to be sitting on their hands waiting for something more to happen. It’s unclear what that trigger will be. Will it be a video interview on major media? Will it be the IND announcement from the FDA? Or will it be an explosion of XBB1.16 cases in India whereby they fast-track the PLM development in the country? Whatever the catalyst, the risk/ reward scenario on BIXT is one of the best in all of the OTC. The small float coupled with the lack of an S-1 on file eliminating the risk of immediate dilution bodes well for either a long-term or medium-term investor.
Investors need to ask themselves if they could have invested in penicillin knowing the impact it was going to have last century would they have dived in? Investors are facing a similar scenario with PLM. This is perhaps the biggest antiviral discovery of the century which amounts to a functional cure for COVID and possibly other viruses. Will investors stay on the sideline because some grumpy shareholder is selling not allowing immediate price discovery or will they step up to secure their place in history? Time will tell, but what is certain is that PLM will save an immeasurable amount of lives and take away untold suffering if it can navigate its way to regulatory approval. But while BIXT may be curing Covid, there is still only one cure for FOMO. Investors would do well to stop waiting on the sidelines to enter or affirm their positions before this game-changing anti-viral goes viral.
Disclosure: MicroCap Daily and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.
Frontera Group Inc (OTCMKTS: FRTG) is making an explosive move northbound in recent trading and is currently under heavy accumulation but still unnoticed by most investors. This is changing quickly as some heavy hitters have jumped on FRTG. The Company is only trading for a $2.7 total valuation with a float of just 3,280,000 FRTG is an SEC filer looking to uplist to OTCQB with a 10k coming out any day. From current levels FRTG has a lot of room to grow. Recently Frontera signed a marketing agreement with Long Side Ventures LLC, following an earlier marketing agreement with Stephen Steen on April 27, 2022.
Earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG. According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Intellimedia Networks is a US and India-based technology company that designs and deploys cloud platforms and applications that create immersive experiences. Intellimedia’s award-winning products utilize AR, VR, and AI to enhance media, training, education, virtual event broadcasting, real estate, and other applications. Frontera brought on business execs Teodros Gessesse and Darshan Sedani.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Frontera Group Inc (OTCMKTS: FRTG) is a strategic acquirer of intellectual property and revenue-generating companies in the technology and human capital markets. It is developing and executing an aggressive, four-tier acquisition and implementation strategy intended to provide substantial increases in profitability to its acquisitions in industries which possess traditionally low and stagnant EBITDA multiples. The Company has identified and is currently pursuing several revenue-generating acquisition targets.
Earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG. According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Intellimedia Networks is a US and India-based technology company that designs and deploys cloud platforms and applications that create immersive experiences. Intellimedia’s award-winning products utilize AR, VR, and AI to enhance media, training, education, virtual event broadcasting, real estate, and other applications.
In connection with the acquisition Teodros Gessesse was appointed as the Chief Marketing Officer of the Company. Mr. Gessesse’s initial annual base salary will be $150,000. Mr. Gessesse will be eligible to receive a quarterly bonus as determined by, and within the sole discretion of, the BOD and was granted 23,500,000 shares of FRTG. Also, Darshan Sedani was appointed as the Chief Visionary Officer of the Company. Mr. Sedani’s initial annual base salary will be $150,000. Mr. Sedani will be eligible to receive a quarterly bonus as determined by, and within the sole discretion of, the BOD and was granted 31,500,000 shares of FRTG. The deal closed on August 17.
$FRTG Our primary objective: To deliver substantial increases in profitability to our acquisitions in mature industries which possess traditionally low and stagnant EBITDA multiples. pic.twitter.com/eTZ6MoHOmE
To Find out the inside Scoop on FRTG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In June FRTG released the 3.0 version of its Mixie Holoport immersive reality framework with Extended Reality (XR) support (“Mixie Holoport XR”). Mixie Holoport XR is a National Association of Broadcasters (NAB) Product of the Year award winner, setting the benchmark for immersive realism in Augmented Reality (AR), Mixed Reality (MR), and Virtual Reality (VR) applications. Frontera recently acquired the Mixie Holoport IP to enhance Metaverse business applications.
Frontera also launched its Mixie AI 2.0 powered live video broadcasting solution that will be targeting automated broadcasting applications. Frontera’s recent acquisition of Intellimedia’s Mixie suite of solutions has provided Frontera with a cutting-edge mix of media technology, learning and training platforms, and event broadcasting technologies that position the company at the technology forefront of a new wave of immersive and engaging technologies that continue to redefine applications. Intellimedia’s Mixie AI 2.0 solutions were utilized for Cricket AI Tata Open Tournament and the ISSF Shooting World Championship to simplify and automate the capture, analysis, discovery, and broadcast of both events. The resulting professional broadcast quality and dramatic cost reduction have become a wake-up call for both organizations to stage and broadcast future events.
Earlier this month FRTG reported it has commenced commercial sales and marketing efforts of Immersient, the intellectual property which was acquired from IntelliMedia Networks, Inc. and formerly sold under the Mixie brand name. Now sold and marketed under the Immersient brand, Frontera’s cloud media platform connects content producers, educational institutions, and event producers with participants and viewers, delivering immersive, personal experiences, interactive participation, existing device compatibility, familiar user conventions, and reliable, “always available” service. The Immersient cloud media platform allows its clients to focus on their core businesses, knowing their end users are enjoying state-of-the-art experiences. With its frictionless device and network independent approach to immersive virtual, augmented, and mixed reality environments, Immersient delivers next-generation group collaboration and communications, interactive distance learning and training, and virtualized events, meetings, expos, conferences, and trade shows.
Currently trading at a $2,7 million market valuation FRTG has 55,563,482 shares outstanding and just 3,280,000 shares in the float. The Company has a clean balance sheet and recently filed a 10Q with a 10k on the way and looking to uplist to OTCQB. FRTG is an exciting story developing in small caps; earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG. According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Earlier this month FRTG reported it has commenced commercial sales and marketing efforts of Immersient, the intellectual property which was acquired from IntelliMedia Networks, Inc. and formerly sold under the Mixie brand name. Now sold and marketed under the Immersient brand, Frontera’s cloud media platform connects content producers, educational institutions, and event producers with participants and viewers, delivering immersive, personal experiences, interactive participation, existing device compatibility, familiar user conventions, and reliable, “always available” service. The stock is currently under heavy accumulation, with big momentum, a little float and some well-known investors jumping on board. We will be updating on FRTG when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FRTG.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in FRTG either long or short and we have not been compensated for this article.
CV Sciences Inc (OTCMKTS: CVSI) is making an explosive move up the charts after the Company announced in a press release and 8K it has extinguished its entire outstanding convertible debt. This is massive news for CVSI which was the number #1 CBD brand on the market but struggled because of the Company’s significant convertible debt load which diluted the stock. That has all been extinguished now and CVSI is racing up the charts. CVSI was one of the biggest runners of 2018 skyrocketing from pennies to over $9 per share when PlusCBD™ sales were booming and the Nasdaq uplist seemed to be around the corner. That all collapsed however not because CVSI was not making sales, they were, but because the Company had significant convertible debt that was decimating the share price.
CVSI is racing up the charts just a penny over all-time lows of $0.0275 and it has a lot of room to grow from current levels. Remember CVSI was one of the biggest runners of 2018 skyrocke3ting to over $9 per share. CVSI is still doing big numbers; Second Quarter 2022 and Recent Financial and Operating Highlights include Revenue of $4.1 million for second quarter of 2022 putting the Company on track to easily top $16 million in sales during fiscal 2022. CVSI is an SEC filer and fully reporting OTCQB and reports its filings in 1000s just like big board Companies do. Now that CVSI has solved the biggest problem that held back its stock for years, currently trading a few pennies over sll time lows and sales as strong as ever speculators are heavily accumulating CVSI and for very good reason, this one ran to over $9 in 2018 and sales are strong with CVSI recently reporting Revenue of $4.1 million for second quarter of 2022.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
CV Sciences Inc (OTCMKTS: CVSI) is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from B2B to B2C. The Company’s PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are one of the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. The Company also operates a drug development division focused on developing and commercializing CBD-based novel therapeutics.
CVSI is still doing big numbers; Second Quarter 2022 and Recent Financial and Operating Highlights include Revenue of $4.1 million for second quarter of 2022, compared to $5.1 million for the second quarter of 2021; Total cash balance of $1.1 million at quarter end, compared to $1.4 million at year end; During Q2 CVSI launched PlusCBD™ Relief softgels to its wellness line of products joining our successful PlusCBD™ Sleep and Calm gummies; the Company Regained position as top-selling hemp extract brand in the natural product retail sales channel, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry; CVSI Continued to evaluate strategic review, including consideration of inbound and outbound merger, sale, acquisition or other options for the Company as a whole or for any business segments anc completed a move to more efficient and cost effective facility in San Diego.
To Find out the inside Scoop on CVSI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On August 25 CVSI announced it has extinguished its entire outstanding convertible debt. This is massive news for CVSI which was the number #1 CBD brand on the market but struggled because of the Company’s significant convertible debt load which diluted the stock. That has all been extinguished now. CV Sciences entered into a Note Purchase Agreement with Streeterville Capital, LLC, in which the Company issued and sold to Streeterville a Secured Promissory Note in the original principal amount of $2,000,000. The Note carries an original issuance discount of $400,000 and the Company agreed to pay $10,000 to Streeterville to cover legal fees, each of which were deducted from the proceeds of the Note received by the Company which resulted in a purchase price received by the Company of $1,590,000. The unpaid amount of the Note, any interest, fees, charges and late fees accrued shall be due and payable in full nine months from August 19, 2022. The Note Agreement required that the Company cancel and terminate the existing Senior Convertible Note dated March 25, 2022 (the “3i Note”) between the Company and 3i, LP (“3i, LP”) in the original principal amount of $1,060,000.
CVSI CEO Joseph Dowling stated: “We have retired all of our outstanding convertible debt which strengthens our balance sheet and helps us with our long-term strategic initiatives. The termination of all convertible debt and related obligations to issue stock to our lender will eliminate the dilutive impact of this debt on our stockholders. In addition, the termination of our convertible debt will eliminate the downward pressure on our stock caused by sale of the shares issued at each conversion event. Our focus is to support our business goals that build shareholder value, and in this regard, we believe eliminating the negative impact of this financing is just as important as continuing to grow our PlusCBD™ branded products business.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $4 million market valuation CVSI was one of the most exciting stocks on the OTCBB making spectacular moves up in 2018 to over $9.20 per share before collapsing on the Citron Research short attack. Currently CVSI is making an explosive move up the charts after the Company announced in a press release and 8K it has extinguished its entire outstanding convertible debt. This is massive news for CVSI which was the number #1 CBD brand on the market but struggled because of the Company’s significant convertible debt load which diluted the stock. That has all been extinguished now and CVSI is racing up the charts. CVSI was one of the biggest runners of 2018 skyrocketing from pennies to over $9 per share when PlusCBD™ sales were booming and the Nasdaq uplist seemed to be around the corner. CVSI is racing up the charts just a penny over all-time lows of $0.0275 and it has a lot of room to grow from current levels. CVSI was one of the biggest runners of 2018 skyrocke3ting to over $9 per share. CVSI is still doing big numbers; Second Quarter 2022 and Recent Financial and Operating Highlights include Revenue of $4.1 million for second quarter of 2022 putting the Company on track to easily top $16 million in sales during fiscal 2022. CVSI is an SEC filer and fully reporting OTCQB and reports its filings in 1000s just like big board Companies do. Now that CVSI has solved the biggest problem that held back its stock for years, currently trading a few pennies over all-time lows and sales as strong as ever speculators are heavily accumulating CVSI and for very good reason, this one ran to over $9 in 2018 and sales are strong with CVSI recently reporting Revenue of $4.1 million for second quarter of 2022. Now that its convertible debt is out of the way CVSI could make another real move. We will be updating on CVSI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CVSI.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CVSI either long or short and we have not been compensated for this article.
Syed Akhter
November 26, 2014 at 12:14 pm
Omagine project just 7 kilo meter distance for Muscat Airport. Beside Wave Muscat first free hold property Oman and Just Opposite North Mawaleh.